[{"orgOrder":0,"company":"Fochon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Fochon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fochon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fochon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Institute of Biological Products","sponsor":"The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"SIBP-R002","moa":"Uric acid","graph1":"Rheumatology","graph2":"Phase I","graph3":"Shanghai Institute of Biological Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Institute of Biological Products \/ The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Institute of Biological Products \/ The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Pegloticase","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"PRX-115","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Urica Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase I","graph3":"Urica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urica Therapeutics \/ Fortress Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Urica Therapeutics \/ Fortress Biotech"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HEC93077","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sunshine Lake Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"HZN-457","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Arrowhead Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SSGJ-613","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NNC4004-0002","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABP-745","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Rheumatology","graph2":"Phase I","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TenNor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TenNor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Department of Health and Human Services | Wellcome Trust","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Rheumatology","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptilogics \/ Department of Health and Human Services | Wellcome Trust","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Department of Health and Human Services | Wellcome Trust"},{"orgOrder":0,"company":"Trellis Bioscience LLC","sponsor":"University of California, Los Angeles | Biomedical Advanced Research and Development Authority | Wellcome Trust | Sinai Hospital of Baltimore | Gulfcoast Research Institute | Phoenix Clinical Research | University of Florida | University of Alabama at Bir","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Calpurbatug","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Trellis Bioscience LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trellis Bioscience LLC \/ University of California, Los Angeles | Biomedical Advanced Research and Development Authority | Wellcome Trust | Sinai Hospital of Baltimore | Gulfcoast Research Institute | Phoenix Clinical Research | University of Florida | University of Alabama at Bir","highestDevelopmentStatusID":"6","companyTruncated":"Trellis Bioscience LLC \/ University of California, Los Angeles | Biomedical Advanced Research and Development Authority | Wellcome Trust | Sinai Hospital of Baltimore | Gulfcoast Research Institute | Phoenix Clinical Research | University of Florida | University of Alabama at Bir"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Vilamakitug","moa":"IL1A","graph1":"Rheumatology","graph2":"Phase I","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"Protalix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"PRX-115","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Protalix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Protalix \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Institute of Biological Products","sponsor":"The First Affiliated Hospital of Bengbu Medical University | The First Affiliated Hospital of Henan University of Science and Technology | Chengdu Fifth People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"SIBP-R002","moa":"Uric acid","graph1":"Rheumatology","graph2":"Phase I","graph3":"Shanghai Institute of Biological Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Institute of Biological Products \/ The First Affiliated Hospital of Bengbu Medical University | The First Affiliated Hospital of Henan University of Science and Technology | Chengdu Fifth People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Institute of Biological Products \/ The First Affiliated Hospital of Bengbu Medical University | The First Affiliated Hospital of Henan University of Science and Technology | Chengdu Fifth People's Hospital"},{"orgOrder":0,"company":"LG Chem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tigulixostat","moa":"enzyme inhibitors: xanthine oxydase and xanthine","graph1":"Rheumatology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Rheumatology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Novilla Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Rheumatology","graph2":"Phase I","graph3":"Novilla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Novilla Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novilla Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IBI128","moa":"Xanthine Dehydrogenase","graph1":"Rheumatology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"VIB1116","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"RenJi Hospital","sponsor":"Westlake Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"WTX221","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"RenJi Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RenJi Hospital \/ Westlake Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"RenJi Hospital \/ Westlake Therapeutics"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"Rui Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KN5501","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ Rui Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ Rui Therapeutics"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABP-745","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Sponsor :
The First Affiliated Hospital of Bengbu Medical University | The First Affiliated Hospital of Henan University of Science and Technology | Chengdu Fifth People's Hospital
Sponsor :
The First Affiliated Hospital of Bengbu Medical University | The First Affiliated Hospital of Henan University of Science and Technology | Chengdu Fifth People's Hospital
Reset All
